Abstract
ABSTRACT
Degenerative ocular diseases are characterized by a convergence of molecular perturbations, including oxidative stress, chronic inflammation, failure of proteostasis, mitochondrial dysfunction, abnormal angiogenic signaling, and biomechanical remodeling. The eye's unique architecture, sealed by the blood‐retina barrier, presents formidable anatomical and cellular topological challenges to achieving long‐term curative therapeutics. Nanotechnology offers an advantage in potential therapy: by utilizing carriers in the nanometer size range and leveraging on appropriate surface modifications, it can effectively overcome these physiological barriers for enhanced, controlled, and targeted treatment. Clinical and preclinical systems such as antioxidant nanoparticles, sustained release implants, anti‐angiogenic nanoplatforms, multifunctional nanocomposites, and regenerative scaffolds illustrate how nanotechnology can overcome limitations in bioavailability, tissue penetration, and pathway specificity in degenerative ocular diseases. Diagnostic advances that include plasmonic contrast agents, quantum dots, graphene biosensors, smart contact lenses, and photothermal neuromodulators further demonstrate continuous molecular surveillance and responsive intervention. Emerging materials such as DNA origami and magnetoelectric nanosystems expand this capability by enabling direct modulation of transcriptional, metabolic, and neuroelectrical pathways. Together, these developments position nanotechnology as a powerful strategy for addressing the molecular origins of ocular degeneration while also highlighting ongoing challenges in long term safety, device stability, manufacturing reproducibility, and regulatory standardization.